{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:17:59Z","timestamp":1794007079497,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Programme EXCELES","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}]},{"name":"St Anne's University Hospital in Brno","award":["IIT\/2022\/02"],"award-info":[{"award-number":["IIT\/2022\/02"]}]},{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF). It is associated with reduced performance, frequent hospitalizations and low quality of life. There is an ongoing debate about the correct definition of ID in HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Refinement of the ID determination in patients with advanced HF. Evaluation of the association of iron metabolism parameters with other clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>One hundred-two patients with advanced HF were included, 48 in-patients, out-patients without LVAD and 25 of patients with LVAD implanted. In addition to conventional tests, we monitored iron metabolism parameters. The prevalence of ID was compared according to both the original and the updated ID definition. Correlations between individual iron markers and patients\u2019 functional capacity were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of ID in patients with advanced HF was 65%. There was no statistically significant difference in individual iron parameters between the groups. All parameters except ferritin correlated with NT-proBNP in the in-patient group. Serum iron correlated most strongly with NT-proBNP and CRP across all groups. The sTfR parameter correlated the most with right heart catheterization parameters, serum iron and TSAT were the most specific parameters related to functional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with more advanced HF and severe limitation of functional capacity had worse iron parameters. Ferritin seems to be the less specific marker of ID, while detecting ID using serum iron and TSAT seems to be reliable. The correlation of ferritin with functional status or haemodynamics was the weakest of all the parameters studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02775-5","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T11:00:50Z","timestamp":1763377250000},"page":"1559-1570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of iron deficiency markers in patients with advanced heart failure"],"prefix":"10.1007","volume":"115","author":[{"given":"Maria","family":"Bakosova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krejci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Godava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ozabalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Poloczkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Honek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Machal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bedanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Nemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2775_CR1","doi-asserted-by":"crossref","unstructured":"Martens P. (2021)The effect of iron deficiency on cardiac function and structure in heart failure with reduced ejection fraction.\u00a0https:\/\/www.cfrjournal.com\/articles\/effect-iron-deficiency-cardiac-function-and-structure-heart-failure-reduced-ejection","DOI":"10.15420\/cfr.2021.26"},{"key":"2775_CR2","doi-asserted-by":"crossref","unstructured":"Alnuwaysir RIS, Hoes MF, van Veldhuisen DJ, van der Meer P, Beverborg NG (2021) Iron deficiency in heart failure: mechanisms and pathophysiology. J Clin Med 11(1):125","DOI":"10.3390\/jcm11010125"},{"key":"2775_CR3","doi-asserted-by":"crossref","unstructured":"Rocha BML, Cunha GJL, Menezes Falc\u00e3o LF (2018) The burden of iron deficiency in heart\u00a0failure: therapeutic approach. J Am Coll Cardiol 71(7):782\u201393","DOI":"10.1016\/j.jacc.2017.12.027"},{"issue":"8","key":"2775_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","volume":"25","author":"F Lindberg","year":"2023","unstructured":"Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ et al (2023) Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail 25(8):1270\u20131280","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2775_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/eurjhf\/hfp140","volume":"11","author":"SD Anker","year":"2009","unstructured":"Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al (2009) Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11(11):1084\u20131091","journal-title":"Eur J Heart Fail"},{"key":"2775_CR6","doi-asserted-by":"crossref","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J 36(11):657\u201368","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"2775_CR7","doi-asserted-by":"crossref","unstructured":"Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317(19):1958\u201366","DOI":"10.1001\/jama.2017.5427"},{"key":"2775_CR8","doi-asserted-by":"crossref","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, B\u00f6hm M, Doletsky A, et al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136(15):1374\u201383","DOI":"10.1161\/CIRCULATIONAHA.117.027497"},{"key":"2775_CR9","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet 396(10266):1895\u2013904","DOI":"10.1016\/S0140-6736(20)32339-4"},{"key":"2775_CR10","doi-asserted-by":"crossref","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet 400(10369):2199\u2013209","DOI":"10.1016\/S0140-6736(22)02083-9"},{"key":"2775_CR11","doi-asserted-by":"publisher","unstructured":"Ferric carboxymaltose in heart failure with iron deficiency | NEJM [Internet]. [cit 20. december 2023]. Available at: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2304968","DOI":"10.1056\/NEJMoa2304968"},{"key":"2775_CR12","doi-asserted-by":"publisher","unstructured":"Prognostic value of three iron deficiency definitions in patients with advanced heart failure - Papadopoulou - 2023 - European Journal of Heart Failure - Wiley Online Library [Internet]. [cit 29. m\u00e1j 2024]. Available at: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ejhf.2949","DOI":"10.1002\/ejhf.2949"},{"key":"2775_CR13","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, et al (2016) Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol 1(5):539\u201347","DOI":"10.1001\/jamacardio.2016.1161"},{"key":"2775_CR14","doi-asserted-by":"crossref","unstructured":"Graham FJ, Friday JM, Pellicori P, Greenlaw N, Cleland JG (2023) Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease. Heart 109(17):1294\u2013301","DOI":"10.1136\/heartjnl-2022-322145"},{"issue":"4","key":"2775_CR15","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/ehf2.12755","volume":"7","author":"K Kurz","year":"2020","unstructured":"Kurz K, Lanser L, Seifert M, Kocher F, P\u00f6lzl G, Weiss G (2020) Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Fail 7(4):1880\u20131890","journal-title":"ESC Heart Fail"},{"key":"2775_CR16","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, et al. Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. Eur J Heart Fail [Internet]. [cit 26. m\u00e1j 2024];n\/a(n\/a). Available at: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/ejhf.3237","DOI":"10.1002\/ejhf.3237"},{"key":"2775_CR17","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al (2023) 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627\u201339","DOI":"10.1093\/eurheartj\/ehad195"},{"issue":"4","key":"2775_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/nop2.168","volume":"5","author":"TW Hsu","year":"2018","unstructured":"Hsu TW, Chang HC, Huang CH, Chou MC, Yu YT, Lin LY (2018) Identifying cut-off scores for interpretation of the Heart Failure Impact Questionnaire. Nurs Open 5(4):575\u2013582","journal-title":"Nurs Open"},{"key":"2775_CR19","doi-asserted-by":"crossref","unstructured":"Packer M (2023) Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in\u00a0combination in heart\u00a0failure. JACC Heart Fail 11(1):106\u201314","DOI":"10.1016\/j.jchf.2022.10.004"},{"key":"2775_CR20","doi-asserted-by":"publisher","unstructured":"Intravenous iron and SGLT2 inhibitors in iron\u2010deficient patients with heart failure and reduced ejection fraction - Docherty - 2024 - ESC Heart Failure - Wiley Online Library [Internet]. [cit 30. j\u00fal 2025]. Available at: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ehf2.14742","DOI":"10.1002\/ehf2.14742"},{"key":"2775_CR21","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Anker SD, Butler J, Filippatos G, Januzzi JL, Schueler E, et al (2025) Effect of empagliflozin on the mechanisms driving erythropoiesis and iron mobilization in patients with heart failure. JACC 85(18):1757\u201370.","DOI":"10.1016\/j.jacc.2025.03.503"},{"key":"2775_CR22","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Kalra PA, Pellicori P, Graham FJ, Foley PWX, Squire IB, et al (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. Eur Heart J 45(16):1410\u201326","DOI":"10.1093\/eurheartj\/ehae243"},{"issue":"4","key":"2775_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1039\/C3MT00347G","volume":"6","author":"DB Kell","year":"2014","unstructured":"Kell DB, Pretorius E (2014) Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Met Integr Biometal Sci apr\u00edl 6(4):748\u2013773","journal-title":"Met Integr Biometal Sci apr\u00edl"},{"issue":"1","key":"2775_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F et al (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail janu\u00e1r 20(1):125\u2013133","journal-title":"Eur J Heart Fail janu\u00e1r"},{"key":"2775_CR25","doi-asserted-by":"crossref","unstructured":"Martens P, Mullens W. Treating iron deficiency in heart failure. N Engl J Med (2023) 389(11):1041\u20132","DOI":"10.1056\/NEJMe2308305"},{"key":"2775_CR26","doi-asserted-by":"crossref","unstructured":"Grote Beverborg N, Klip IjT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, et al (2018) Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail 11(2):e004519","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519"},{"key":"2775_CR27","doi-asserted-by":"crossref","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Mr\u00e1zkov\u00e1 J, \u0160ramko M, Kotr\u010d M, \u017del\u00edzko M, et al (2024) Iron deficiency and all-cause mortality after myocardial infarction. Eur J Intern Med S0953\u20136205(24)00180\u20138","DOI":"10.1016\/j.ejim.2024.04.020"},{"key":"2775_CR28","doi-asserted-by":"crossref","unstructured":"Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al (2021) The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy\u2014the IRON-CRT trial. Eur Heart J 42(48):4905\u201314","DOI":"10.1093\/eurheartj\/ehab411"},{"key":"2775_CR29","doi-asserted-by":"crossref","unstructured":"Ueda T, Kawakami R, Nogi K, Nogi M, Ishihara S, Nakada Y, et al (2021) Serum iron: a new predictor of adverse outcomes independently from serum hemoglobin levels in patients with acute decompensated heart failure. Sci Rep 11(1):2395","DOI":"10.1038\/s41598-021-82063-0"},{"issue":"6","key":"2775_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ejhf.2036","volume":"23","author":"R Sierpinski","year":"2021","unstructured":"Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A et al (2021) High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail 23(6):919\u2013932","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02775-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:55:39Z","timestamp":1786348539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02775-5","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was conducted following the Declaration of Helsinki and the required ethics 79 committee decision for the study was received from the Local Ethics Committee (IIT\/2022\/02).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}